These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 18195685)

  • 1. Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation.
    Hill QA; Hill A; Collyns TA; Pearce RM; Cook G
    Bone Marrow Transplant; 2008 Apr; 41(8):749-51. PubMed ID: 18195685
    [No Abstract]   [Full Text] [Related]  

  • 2. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin.
    Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Kim SH; Kim HJ; Cho SG; Eom KS; Lee JW; Min WS; Shin WS; Kim CC
    Transpl Infect Dis; 2009 Oct; 11(5):413-23. PubMed ID: 19708893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
    Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT
    Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.
    Peggs KS; Sureda A; Qian W; Caballero D; Hunter A; Urbano-Ispizua A; Cavet J; Ribera JM; Parker A; Canales M; Mahendra P; Garcia-Conde J; Milligan D; Sanz G; Thomson K; Arranz R; Goldstone AH; Alvarez I; Linch DC; Sierra J; Mackinnon S;
    Br J Haematol; 2007 Oct; 139(1):70-80. PubMed ID: 17854309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
    Delgado J; Pillai S; Benjamin R; Caballero D; Martino R; Nathwani A; Lovell R; Thomson K; Perez-Simon JA; Sureda A; Kottaridis P; Vazquez L; Peggs K; Sierra J; Milligan D; Mackinnon S
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1288-97. PubMed ID: 18940684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab.
    Lamba R; Carrum G; Myers GD; Bollard CM; Krance RA; Heslop HE; Brenner MK; Popat U
    Bone Marrow Transplant; 2005 Nov; 36(9):797-802. PubMed ID: 16151431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML.
    Malladi RK; Peniket AJ; Littlewood TJ; Towlson KE; Pearce R; Yin J; Cavenagh JD; Craddock C; Orchard KH; Olavarria E; McQuaker G; Collin M; Marks DI;
    Bone Marrow Transplant; 2009 May; 43(9):709-15. PubMed ID: 19029965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of cytomegalovirus (CMV) sero-positivity on CMV infection, lymphocyte recovery and non-CMV infections following T-cell-depleted allogeneic stem cell transplantation: a comparison between two T-cell depletion regimens.
    Chakrabarti S; Milligan DW; Brown J; Osman H; Vipond IB; Pamphilon DH; Marks DI
    Bone Marrow Transplant; 2004 Jan; 33(2):197-204. PubMed ID: 14647256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath "in the bag" as T-cell depletion: the Leiden experience.
    Barge RM; Starrenburg CW; Falkenburg JH; Fibbe WE; Marijt EW; Willemze R
    Bone Marrow Transplant; 2006 Jun; 37(12):1129-34. PubMed ID: 16757974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CMV infection following nonmyeloablative allogeneic stem cell transplantation using Campath.
    Bainton RD; Byrne JL; Davy BJ; Russell NH
    Blood; 2002 Nov; 100(10):3843-4. PubMed ID: 12411329
    [No Abstract]   [Full Text] [Related]  

  • 12. Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab.
    Avivi I; Chakrabarti S; Milligan DW; Waldmann H; Hale G; Osman H; Ward KN; Fegan CD; Yong K; Goldstone AH; Linch DC; Mackinnon S
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):186-94. PubMed ID: 14993884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience.
    Piñana JL; Martino R; Barba P; Margall N; Roig MC; Valcárcel D; Sierra J; Rabella N
    Bone Marrow Transplant; 2010 Mar; 45(3):534-42. PubMed ID: 19668235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of busulfan, cladribine and alemtuzumab as reduced intensity conditioning for stem cell transplantation.
    Halaburda K; Marianska B; Warzocha K; Nasilowska-Adamska B; Szczepinski A; Tomaszewska A; Sawecka J; Skulimowska J
    Ann Transplant; 2009; 14(2):7-12. PubMed ID: 19487787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes.
    Lim ZY; Pearce L; Ho AY; Barber L; Ingram W; Usai M; Tobal K; Devereux S; Pagliuca A; Mufti GJ
    Br J Haematol; 2007 Aug; 138(4):517-26. PubMed ID: 17608767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paraproteinaemia after allo-SCT, association with alemtuzumab-based conditioning and CMV reactivation.
    Medd P; Littlewood S; Danby R; Malladi R; Clifford R; Wareham D; Jeffery K; Ferry B; Roberts D; Peniket A; Littlewood T
    Bone Marrow Transplant; 2011 Jul; 46(7):993-9. PubMed ID: 20956951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-index as a novel index to evaluate both the intensity and duration of lymphopenia after allogeneic hematopoietic stem cell transplantation.
    Kimura SI; Wada H; Sakamoto K; Ashizawa M; Sato M; Terasako K; Nakasone H; Kikuchi M; Okuda S; Kako S; Yamazaki R; Oshima K; Tanaka Y; Tanihara A; Nishida J; Kanda Y
    Transpl Infect Dis; 2012 Aug; 14(4):364-73. PubMed ID: 22469427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
    Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
    Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus retinitis after hematopoietic stem cell transplantation with alemtuzumab.
    Song WK; Min YH; Kim YR; Lee SC
    Ophthalmology; 2008 Oct; 115(10):1766-70. PubMed ID: 18562004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alemtuzumab-based reduced-intensity conditioning allogeneic transplantation for myeloma and plasma cell leukemia - a single-institution experience.
    Ramasamy K; Mahmood S; Lim Z; Corderoy S; Devereux S; Mufti GJ; Pagliuca A; Schey S
    Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):242-5. PubMed ID: 21575930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.